Market News

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSXV: GRA, TSX: GRA and OTCQX: NNXPF) is pleased to announce that the Corporation's common shares will begin trading on the Toronto Stock Exchange (the " TSX ") on July 15, 2021, following the Corporation's graduation from the TSX Venture Exchange (the " TSXV "). The common shares of the Corporation will be concurrently delisted from the TSXV upon commencement of trading on the TSX. The trading symbol for the common shares of NanoXplore on the TSX will remain unchanged as "GRA" and shareholders are not required to take any action.

"The listing of the Corporation's common shares on the TSX further enhances our profile and exposure as we look forward to connecting with a wider audience of the investment community" added Dr. Soroush Nazarpour, President and Chief Executive Officer of NanoXplore.

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. NanoXplore provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Soroush Nazarpour
President and Chief Executive Officer
NanoXplore Inc.
(514) 935-1377
info@NanoXplore.ca


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

NanoXplore Reports Fourth Quarter and Year Ended 2022 Financial Results

NanoXplore Inc. ("NanoXplore" or "the Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the quarter and year ended June 30, 2022.

All amounts in this press release are in Canadian dollars, unless otherwise stated.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Inc. to Host a Webcast to Discuss Fourth Quarter Results on Thursday September 15, 2022

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its fourth quarter ended June 30, 2022, on Thursday, September 15, 2022, at 8:30 a.m. Eastern Time. The financial results will be released on Wednesday September 14, 2022, after the market close.

Details of the Q4 Webcast

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Acquires Assets of XG Sciences

NanoXplore Inc. (" NanoXplore ") (TSX: GRA and OTCQX: NNXPF), world-leading graphene company, is pleased to announce today that it was the winning bidder for a significant portion of the assets of XG Sciences Inc. (" XG Sciences ", " XG ", or the " Company ") in a sale conducted by XG's senior secured creditor pursuant to Article 9 of Michigan's enactment of the Uniform Commercial Code. NanoXplore and the senior creditor have entered into an asset purchase agreement pursuant to which NanoXplore is acquiring XG's mechanical milling platform, research and development lab and all issued and pending patents and trademarks, among other items. The payment of this transaction is paid in cash without any share issuance.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Inc.

Universal Ibogaine Inc.

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney

Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×